After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...
Reminder - The CTS Reentry form, CTS-00172, will be updated on Monday July 2, 2018. It's posted ...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
Reminder - On Wednesday June 6, 2018 at 10:00AM PST, we will be hosting a webinar regarding the chan...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...